If you have been reading about ACTH analog and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It corresponds to the ACTH(4-7) fragment extended at the C-terminus by a Pro-Gly-Pro tripeptide, an addition intended to slow enzymatic breakdown. The molecular formula is C37H51N9O10S and the molecular mass is approximately 814 daltons. In the literature it is often described as an ACTH(4-10) analog, although that label reflects a naming convention as much as a precise structural relationship. The compound was developed in Russia and remains most closely associated with that research tradition.
Laboratory descriptions of the material are consistent across suppliers. It appears as a white to off-white lyophilized powder that dissolves readily in water and in polar organic solvents such as dimethyl sulfoxide. Aqueous solutions are clear and colorless at low concentrations. Because the peptide contains methionine, oxidation at the sulfur atom is a recognized degradation pathway, and handling notes usually call for protected, desiccated storage. Reported purity for research-grade lots is generally above 95 percent as measured by reversed-phase high-performance liquid chromatography.
The compound is registered in Russia as a pharmaceutical product, most commonly formulated as a nasal solution, and has been used in that setting since the 1990s. Outside that jurisdiction it is generally handled as a research chemical rather than an approved medicine. Regulatory status therefore differs sharply between countries, and material sold internationally may not correspond to the Russian pharmaceutical formulation. Documentation with commercial samples is typically limited to a certificate of analysis covering purity and identity, not clinical status or local legal classification.
Russian regulatory authorities approved the peptide for nasal administration, and it remains listed in the national pharmacopoeia under several trade names. Documented indications include acute ischemic stroke, transient ischemic attacks, traumatic brain injury, and certain ophthalmological and neurological conditions. Physicians also prescribe it for cognitive complaints in older patients, although the evidence base for that use is thinner. Outside Russia and a few neighboring states, the substance is not an approved medicine and is sold instead as a research chemical.
Later generations of the molecule include an N-acetylated form and an amidated form, both marketed online alongside the parent peptide. These variants differ in terminal chemistry and stability, and they are frequently discussed in the same breath even though they have not been compared in controlled trials. Supply outside formal healthcare systems comes largely from laboratories that synthesize peptides to order. Purity and identity of these materials vary widely, and no single body oversees the international trade.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C37H51N9O10S | Contains one methionine sulfur atom |
| Molecular mass | Approximately 814 Da | Consistent with a seven-residue peptide |
| Appearance | White to off-white powder | Typical lyophilized form |
| Solubility | Freely soluble in water | Also soluble in dimethyl sulfoxide |
| Typical storage | -20 °C, desiccated | Limits methionine oxidation |
Regulatory status varies sharply by country. Semax is registered for medical use in Russia, where it appears in formularies as a nasal solution, and it also holds registration in a small number of neighbouring states. It has no approval from the United States Food and Drug Administration or the European Medicines Agency, and it is not a scheduled controlled substance in most jurisdictions. Elsewhere it circulates mainly as laboratory material, so purity documentation comes from suppliers rather than from a national pharmacopoeia.
Semax is a synthetic peptide created in the Soviet Union during the early 1980s by researchers working in Moscow. It was built from the short adrenocorticotropic hormone fragment known as ACTH(4-10), and the chain was then extended with three additional amino acids. The resulting molecule was named semax and entered clinical use in Russia in 1994. It is generally described as a nootropic and neuroprotective agent rather than as a hormone analogue.
The parent fragment ACTH(4-10) carries the sequence Met-Glu-His-Phe-Arg-Trp-Gly. Semax replaces the arginine and tryptophan positions with a proline-glycine-proline tail, giving Met-Glu-His-Phe-Pro-Gly-Pro. That change removes residues associated with adrenal stimulation, so the peptide does not drive cortisol release the way full ACTH does. This distinction shapes how the compound is grouped in the literature, where it sits with neuropeptides and peptide neuromodulators rather than with corticosteroids.
"Exporting pine nuts to Europe". Center for the Promotion of Imports. 24 April 2019. Archived from the original on 3 January 2023. Retrieved 3 January 2023. Charles, Dan (8 October 2014). "Love Pine Nuts? Then Protect Pine Forests". NPR. Retrieved 19 April 2015.
NMNH (Dihydronicotinamide mononucleotide), also known as reduced nicotinamide mononucleotide. Both NMNH and NMN increase NAD+ levels in the body. NAD+ is a universal coenzyme that plays vital roles in nearly all living organisms functioning in various biological processes such as metabolism, cell signaling, gene regulation, and DNA repair.
Humans exhibit a variety of abilities. This includes an ability of emotional Hedonic Adaptation, an idea suggesting that beauty, fame and money do not generally have lasting effects on happiness (this effect has also been called the Hedonic treadmill). In this vein, some research has suggested that only recent events, meaning those that occurred within the last 3 months, affect happiness levels. The tendency to adapt, and therefore return to an earlier level of happiness, is illustrated by studies showing lottery winners are no happier in the years after they've won. Other studies have shown paraplegics are nearly as happy as control groups that are not paralyzed, after equally few years. Daniel Kahneman explains: "they are not paraplegic full time... It has to do with allocation of attention". Thus, contrary to our impact biases, lotteries and paraplegia do not change experiences to as great a degree as we would believe. However, in a newer study (2007), winning a medium-sized lottery prize had a lasting mental wellbeing effect of 1.4 GHQ points on Britons even two years after the event. Moreover, adaptation can be a very slow and incomplete process. Distracting life changes such as the death of a spouse or losing one's job can show measurable changes in happiness levels for several years. Even the "adapted" paraplegics mentioned above did ultimately report lower levels of pleasure (again, they were happier than one would expect, but not fully adapted).
== Development == The CPT was originally built for the Tandem Accelerator Superconducting Cyclotron (TASCC) facility at Chalk River Laboratories in Chalk River, Ontario, Canada. However, it was transferred to Argonne National Laboratory when the TASCC accelerator was decommissioned in 1998 due to funding issues. The CPT spectrometer is designed to provide high-precision mass measurements of short-lived isotopes using radio-frequency (RF) fields. Accurate mass measurements of particular isotopes such as selenium-68 are important in the understanding of the detailed reaction mechanisms involved in the rapid-proton capture process, which occurs in astrophysical events like supernovae explosions and X-ray bursts. An X-ray burst is one possible site for the rp-process mechanism which involves the accretion of hydrogen and helium from one star onto the surface of its neutron star binary companion. Mass measurements are required as key inputs to network calculations used to describe this process in terms of the abundances of the nuclides produced, the light-curve profile of the X-ray bursts, and the energy produced. In the current configuration, more than 100 radioactive isotopes have been measured with half-lives much less than a second and with a precision (Δm/m) approaching 10−9. Recently, a novel injection system, the RF gas cooler, has been installed on the CPT to allow fast reaction products to be decelerated, thermalized and bunched for rapid and efficient injection.
Sources: en.wikipedia.org
The hypothalamus has a central neuroendocrine function, most notably by its control of the anterior pituitary, which in turn regulates various endocrine glands and organs. Releasing hormones (also called releasing factors) are produced in hypothalamic nuclei then transported along axons to either the median eminence or the posterior pituitary, where they are stored and released as needed.
Saint Kitts and Nevis - The Scout Association of Saint Kitts and Nevis* Tonga - Tonga branch of The Scout Association* Tuvalu - Tuvalu Scout Association* Vanuatu - Vanuatu branch of The Scout Association* Served by Scouts Australia
=== Malaria === Malaria and vitamin A deficiency are both common among young children in sub-Saharan Africa. Vitamin A supplementation to children in regions where vitamin A deficiency is common has repeatedly been shown to reduce overall mortality rates, especially from measles and diarrhea. For malaria, clinical trial results are mixed, either showing that vitamin A treatment did not reduce the incidence of probable malarial fever, or else did not affect incidence, but did reduce slide-confirmed parasite density and reduced the number of fever episodes. The question was raised as to whether malaria causes vitamin A deficiency, or vitamin A deficiency contributes to the severity of malaria, or both. Researchers proposed several mechanisms by which malaria (and other infections) could contribute to vitamin A deficiency, including a fever-induced reduction in synthesis of retinal-binding protein (RBP) responsible for transporting retinol from liver to plasma and tissues, but reported finding no evidence for a transient depression or restoration of plasma RBP or retinol after a malarial infection was eliminated.
The Fifth Coalition (1809) of Britain and Austria against France formed as Britain engaged in the Peninsular War in Spain and Portugal. The sea became a major theatre of war against Napoleon's allies. Austria, previously an ally of France, took the opportunity to attempt to restore its imperial territories in Germany as held prior to Austerlitz. During the time of the Fifth Coalition, the Royal Navy won a succession of victories in the French colonies. On land the major battles included Battles of Raszyn, Eckmuhl, Raab, Aspern-Essling, and Wagram. On land, the Fifth Coalition attempted few extensive military endeavours. One, the Walcheren Expedition of 1809, involved a dual effort by the British Army and the Royal Navy to relieve Austrian forces under intense French pressure. It ended in disaster after the Army commander, John Pitt, 2nd Earl of Chatham, failed to capture the objective, the naval base of French-controlled Antwerp. For the most part of the years of the Fifth Coalition, British military operations on land (apart from the Iberian Peninsula) remained restricted to hit-and-run operations executed by the Royal Navy, which dominated the sea after having beaten down almost all substantial naval opposition from France and its allies and blockading what remained of France's naval forces in heavily fortified French-controlled ports. These rapid-attack operations were aimed mostly at destroying blockaded French naval and mercantile shipping and the disruption of French supplies, communications, and military units stationed near the coasts.
=== MeSH D12.644.641 – peptides, cyclic === MeSH D12.644.641.040 – alamethicin MeSH D12.644.641.050 – amanitins MeSH D12.644.641.075 – bacitracin MeSH D12.644.641.142 – capreomycin sulfate MeSH D12.644.641.235 – cyclosporins MeSH D12.644.641.235.300 – cyclosporine MeSH D12.644.641.243 – cyclotides MeSH D12.644.641.252 – dactinomycin MeSH D12.644.641.270 – daptomycin MeSH D12.644.641.297 – depsipeptides MeSH D12.644.641.297.500 – valinomycin MeSH D12.644.641.325 – echinomycin MeSH D12.644.641.380 – ferrichrome MeSH D12.644.641.515 – mycobacillin MeSH D12.644.641.548 – nanotubes, peptide MeSH D12.644.641.582 – nisin MeSH D12.644.641.650 – octreotide MeSH D12.644.641.735 – phalloidine MeSH D12.644.641.780 – polymyxins MeSH D12.644.641.780.110 – colistin MeSH D12.644.641.780.750 – polymyxin b MeSH D12.644.641.802 – streptogramins MeSH D12.644.641.802.249 – mikamycin MeSH D12.644.641.802.374 – pristinamycin MeSH D12.644.641.802.500 – streptogramin group a MeSH D12.644.641.802.500.500 – streptogramin a MeSH D12.644.641.802.750 – streptogramin group b MeSH D12.644.641.802.750.500 – streptogramin b MeSH D12.644.641.802.812 – vernamycin b MeSH D12.644.641.802.875 – virginiamycin MeSH D12.644.641.802.875.500 – streptogramin a MeSH D12.644.641.825 – thiostrepton MeSH D12.644.641.875 – viomycin MeSH D12.644.641.875.250 – enviomycin
Sources: en.wikipedia.org
It is registered as a pharmaceutical product in Russia, where it is typically supplied as a nasal solution. In most other countries it is not an approved drug and is traded as a research chemical instead. Approval status depends entirely on the jurisdiction involved.
Most published work uses intranasal administration, matching the route of the registered Russian formulation. Some animal experiments use intravenous or intraperitoneal injection. The route matters because the intact peptide is cleared rapidly from blood, so exposure differs between methods.
A purity value describes the share of the powder accounted for by the target peptide, usually by high-performance liquid chromatography. It does not confirm that the sequence is correct, which requires mass spectrometry or amino acid analysis. Purity and identity are separate checks.
It originated at the Institute of Molecular Genetics in Moscow during the 1980s. The work was carried out by a Russian research group that specialized in peptide neuropharmacology.